Xeltis has completed the first commercial implantation of its aXess [...]
Xeltis has passed the halfway enrolment mark in its US [...]
Xeltis’ aXess EU key trial shows sustained patency, fewer interventions, [...]
Xeltis has announced successful clinical data from its aXess EU [...]